NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; NTBI 1301; NY ESO-1 loaded dendritic cell vaccine
- Indications Solid tumours
- Focus Adverse reactions
- 12 Sep 2017 Planned End Date changed from 1 Feb 2019 to 17 Jul 2020.
- 12 Sep 2017 Planned primary completion date changed from 1 Feb 2019 to 17 Jul 2019.
- 08 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.